Premium
Effect of Prazosin and Beta‐Blocker Monotherapy on Serum Lipids: A Cross‐Over, Placebo‐Controlled Study
Author(s) -
Magarian Edward O.,
Dietz Albert J.,
Freeman David S.,
Carlson James D.
Publication year - 1987
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1987.tb02992.x
Subject(s) - medicine , prazosin , cholesterol , placebo , triglyceride , endocrinology , beta blocker , blood lipids , antagonist , heart failure , alternative medicine , receptor , pathology
The effects of prazosin and beta‐blocker monotherapy on serum concentrations of triglycerides, cholesterol, and lipoprotein cholesterol were evaluated in 16 patients with mild to moderate essential hypertension in a single‐blind, cross‐over, placebo‐controlled study. Initially patients received a bid dose of either prazosin or a beta‐blocker sufficient to maintain a sitting diastolic pressure below 95 mm Hg. After a placebo washout, patients were placed on the alternate medication. Fasting serum samples were obtained for lipid analysis during each treatment phase. Beta‐blocker therapy was associated with undesirable changes in serum lipids as evidenced by increases in the concentration of total triglyceride (45%, P = .001), total cholesterol (4%, P = .05), LDL cholesterol (6%, P = .05) and VLDL cholesterol (21%, P = .05), and a decrease in the concentration of HDL cholesterol (‐9%, P = .05). The ratios of total cholesterol to HDL cholesterol and LDL cholesterol to HDL cholesterol also increased by 15% (P = .005) and 18% (P = .005), respectively. No significant changes in any of the serum lipids were observed during prazosin administration.